Nipro (NPRRF) Change In Receivables : $0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Nipro Change In Receivables?

Nipro's change in receivables for the quarter that ended in Dec. 2023 was $0 Mil. It means Nipro's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

Nipro's change in receivables for the fiscal year that ended in Mar. 2024 was $52 Mil. It means Nipro's Accounts Receivable declined by $52 Mil from Mar. 2023 to Mar. 2024 .

Nipro's Accounts Receivable for the quarter that ended in Dec. 2023 was $1,267 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Nipro's Days Sales Outstanding for the three months ended in Dec. 2023 was 108.62.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Nipro's liquidation value for the three months ended in Dec. 2023 was $-3,473 Mil.

Nipro Change In Receivables Historical Data

The historical data trend for Nipro's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nipro Change In Receivables Chart

Nipro Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Change In Receivables

Get a 7-Day Free Trial

-24.63

96.86

56.16

-83.14

52.36

Nipro Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Nipro Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

Nipro (OTCPK:NPRRF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Nipro's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1267.198	/	1064.512	*	91
=	108.62

2. In Ben Graham's calculation of liquidation value, Nipro's accounts receivable are only considered to be worth 75% of book value:

Nipro's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	551.633	-	5773.471	+	0.75 * 1267.198	+	0.5 * 1596.747
=	-3,473

Nipro Change In Receivables Related Terms

Thank you for viewing the detailed overview of Nipro's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Nipro (NPRRF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nipro Corp (OTCPK:NPRRF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

8086:Japan

Address

3-9-3 Honjo-Nishi Kita-ku, Osaka, JPN, 531-8510

Website

http://www.nipro.co.jp

Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.

Nipro (NPRRF) Headlines

No Headlines